Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Jean Baptiste Alberge Clear advanced filters

  • The genomic features of precursor conditions of multiple myeloma provide multiple biological insights into disease origins and evolution, together with opportunities to identify those at highest risk of progression.

    • Jean-Baptiste Alberge
    • Ankit K. Dutta
    • Irene M. Ghobrial
    ResearchOpen Access
    Nature Genetics
    Volume: 57, P: 1493-1503

  • Lightbody et al. present SWIFT-seq, a single-cell RNA sequencing approach to profile circulating tumor cells from patients with multiple myeloma and its precursor conditions and leverage it to derive clinical and biological insights into the disease.

    • Elizabeth D. Lightbody
    • Romanos Sklavenitis-Pistofidis
    • Irene M. Ghobrial
    Research
    Nature Cancer
    Volume: 6, P: 1595-1611

  • Tumor-intrinsic resistance mechanisms, including mutational events and immunoselection of mutant clones, were identified in 30 patients with multiple myeloma who experienced relapse after treatment with anti-BCMA CAR T cells and/or anti-BCMA bispecific T cell engagers (TCEs) or anti-GPRC5D TCE therapy.

    • Holly Lee
    • Sungwoo Ahn
    • Nizar J. Bahlis
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 2295-2306

  • In a systematic review and meta-analysis of nonrelapse mortality (NRM) following CAR T cell treatment in 7,604 patients with lymphoma and myeloma, almost half of cases were atrributable to infections and NRM estimates varied across both tumor types and CAR T cell products

    • David M. Cordas dos Santos
    • Tobias Tix
    • Kai Rejeski
    Research
    Nature Medicine
    Volume: 30, P: 2667-2678

  • Multiple myeloma is a plasma cell malignancy that is currently incurable. Cordas dos Santos et al. describe how multiple myeloma arises from precursor states and how T cell-redirecting therapies might be used to intercept disease progression at these earlier stages to improve patient outcomes.

    • David M. Cordas dos Santos
    • Rosa Toenges
    • Irene M. Ghobrial
    Reviews
    Nature Reviews Cancer
    Volume: 24, P: 867-886

  • Multiple myeloma and its precursor stages, monoclonal gammopathy of undetermined significance and smouldering multiple myeloma, have a considerable degree of genetic heterogeneity. The authors of this Review discuss how single-cell studies in these individuals are enabling the mutational and phenotypic characterization of cells within the bone marrow tumour, immune microenvironment and peripheral blood to eventually guide early diagnosis, risk stratification and treatment strategies.

    • Ankit K. Dutta
    • Jean-Baptiste Alberge
    • Irene M. Ghobrial
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 19, P: 223-236